Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
Paris, France, June 14, 2022 – Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced positive MRI scans before and after therapeutic ultrasound treatment to assess the risk of stroke.
We are excited to today announce the 42 promising start-ups that will go through to the semifinals of EIT Health Catapult 2022-23. Each year, the competition showcases Europe’s most promising biotech, medtech and digital health start-ups to leading experts and investors. Many participants of the competition have gone on to excel in their respective fields.
We are proud to announce the launch of Vik Colorectal in Spain! Developed with the institutional support of Pierre Fabre Group, our newest virtual companion will support patients and their loved ones living with colorectal cancer!
Paris, May 16, 2022 – PKvitality, a French company specializing in Bio-wearable Health and Sports, has been selected to join the 1st promotion of Future4care, the largest eHealth accelerator in Europe.
Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.
The European Stroke Organisation (ESO) is a pan-European society of stroke researchers and physicians, national and regional stroke societies and lay organisations that was founded in December 2007. The ESO is an NGO comprised of individual and organisational members.
Digital Health Innovation: Affidea Signs Partnership With Incepto To Integrate Multi-AI Solutions
Affidea, the largest European provider of advanced diagnostics, outpatient and cancer care services announces a strategic partnership with Incepto, supplier and creator of artificial intelligence solutions in the medical, sector.
|LATTICE MEDICAL DEMARRE SES ESSAIS CLINIQUES 🚀|
Et voilà nous y sommes ! Après 3 ans de travail, nous annonçons le démarrage de nos essais cliniques et l’inclusion d’une première patiente éligible à la reconstruction mammaire avec #MATTISSE dans le cadre de son cancer du sein.
French medtech companies are tackling diabetes and innovating, as proven by the sheer number of patents filed in 2021. Each year, the National Industrial Property Institute (INPI)ranks the top patent filers, highlighting companies that invest in innovation.
Latest Insights
We are excited to today announce the 42 promising start-ups that will go through to the semifinals of EIT Health Catapult 2022-23. Each year, the competition showcases Europe’s most promising biotech, medtech and digital health start-ups to leading experts and investors. Many participants of the competition have gone on to excel in their respective fields.
Paris, January 28, 2022 – PKvitality, a French company specializing in bio-wearables, finalized a funding round of €6m, including an investment from the EIC Fund (European Innovation Council Fund). Other contributors to this round are Business Angels, EIT Health, alongside current investors on board, including Beurer GmbH. This round will accelerate the development of K’Watch Glucose, a Continuous Glucose Monitor (CGM) embedded in a smartwatch for diabetes patients.
Paris, October 16, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including
Paris, May 16, 2022 – PKvitality, a French company specializing in Bio-wearable Health and Sports, has been selected to join the 1st promotion of Future4care, the largest eHealth accelerator in Europe.
Paris, France, June 29, 2022 – 6:00 p.m. CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specialized in the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces that the European Patent Office (EPO) has granted a new patent that strengthens Acticor Biotech’s patent portfolio. It provides protection for the use of glenzocimab in thrombotic diseases in Europe until 2036.